IP Library Granted Patent US 7,390,795
Granted Patent B2
US 7,390,795 · App. 09/737,544 · Granted Jun 24, 2008

Treatment and prevention of tissue damage

Assignee: Pentraxin Therapeutics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,795
App. No.
09/737,544
Granted
Jun 24, 2008
Kind
B2
Abstract

A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.

Claims (11)

1. A method for reducing damage to heart muscle caused by C-reactive protein (CRP) in a patient who has suffered ischemic necrosis and is in need thereof, comprising inhibiting CRP binding to its ligands in vivo in the patient, by administering to the patient an effective amount of a compound that comprises phosphocholine or a derivative thereof, wherein the compound has the general formula (II)

wherein X is H or C 1 to C 20 hydrocarbyl, and Y is N substituted to form ammonium.

2. The method of claim 1 wherein the compound is bound by the calcium-dependent ligand binding site of CRP.

3. The method of claim 1 , wherein X is C 1 to C 20 alkyl.

4. The method of claim 3 , wherein X is C 1 to C 20 alkyl.

5. A method for reducing tissue damage caused by C-reactive protein (CRP) in a patient in need thereof who has suffered an inflammatory or tissue damaging condition comprising inhibiting CRP binding to its ligands in vivo within the patient, by administering to the patient an effective amount of a compound that comprises phosphocholine or a derivative thereof, wherein the compound has the general formula (II)

wherein X is H or C 1 to C 20 hydrocarbyl, and Y is N substituted to form ammonium.

6. The method of claim 5 wherein the compound is bound by the calcium-dependent ligand binding site of CRP.

7. The method of claim 5 , wherein X is C 1 to C 20 alkyl.

8. The method of claim 7 , wherein X is C 12 to C 20 alkyl.

9. The method of claim 5 , wherein the inflammatory or tissue damaging condition is selected from one or more of ischemic necrosis or stroke.

Assignments (3)
CHANGE OF ASSIGNEE ADDRESS Recorded Jan 10, 2012
From: PENTRAXIN THERAPEUTICS LIMITED
To: PENTRAXIN THERAPEUTICS LIMITED
Reel/Frame 027506/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2004
From: UNIVERSITY COLLEGE LONDON
To: PENTRAXIN THERAPEUTICS LIMITED
Reel/Frame 014544/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2001
From: PEPYS, MARK B.
To: UNIVERSITY COLLEGE LONDON
Reel/Frame 011940/0377 →
Continuity (1)
Related Publication 20030171251A1 · Sep 11, 2003